Drugs / RUTI®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05136833 | Dec 2021 → Jun 2022 | tuberculosis | Archivel Farma S.L. | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-20 | Archivel Farma S.L. | Results RUTI® in combination with BCG Therapy Show Encouraging Outcomes in Bladder Cancer archivelfarma.com ↗
Administered prior to standard BCG therapy, RUTI ® enhanced the immune response, reducing tumor recurrence and progression, and improving patient survival over five years. |
| 2023-11-09 | Archivel Farma S.L. | Results Significant efficacy of RUTI® vaccine in a non-clinical study of active tuberculosis archivelfarma.com ↗
A recent non-clinical study has demonstrated the potential of the therapeutic vaccine RUTI ® in treating tuberculosis (TB) in mice. |
| 2014-02-28 | Archivel Farma S.L. | Results Results of RUTI ® ‘s Phase II clinical trial, published in Plos One archivelfarma.com ↗
The article, signed by Andre S. Nell, 1 Eva D’lom, 2 Patrick Bouic, 3 Montserrat Sabaté, 4 Ramon Bosser, 5 Jordi Picas, 6 Mercè Amat, 6 Gavin Churchyard, 7 i Pere-Joan Cardona 6,8 , comes to the conclusion that this Phase II clinical trial demonstrates reasonable tolerability of RUTI ® . |
All press releases naming this drug 10 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RUTI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05136833 ↗ |
| Modality | Vaccine | “a vaccine against tuberculosis (RUTI®)” NCT05136833 ↗ |
| Route | Subcutaneous | “It will be administered subcutaneously in the deltoid region at a dose of 25 µg” NCT05136833 ↗ |